Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nesiritide (Scios).

Andrew J Burger1, Mary R Burger

  • 1Beth Israel Deaconess Medical Center, Non-invasive Cardiology Laboratory, Baker-3, 1 Deaconess Road, Boston, MA 02215, USA. aburger@caregroup.harvard.edu

Idrugs : the Investigational Drugs Journal
|June 13, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hemodynamics of the diastolic pressure gradients in acute heart failure: implications for the diagnosis of pre-capillary pulmonary hypertension in left heart disease.

Pulmonary circulation·2018
Same author

Diuretic Response: Clinical and Hemodynamic Predictors and Relation to Clinical Outcome.

Journal of cardiac failure·2015
Same author

Fluid loss, venous congestion, and worsening renal function in acute decompensated heart failure.

European journal of heart failure·2013
Same author

Hemodynamic determinants of dyspnea improvement in acute decompensated heart failure.

Circulation. Heart failure·2012
Same author

Ambient air pollution and the risk of acute ischemic stroke.

Archives of internal medicine·2012
Same author

Crescendo in depolarization and repolarization heterogeneity heralds development of ventricular tachycardia in hospitalized patients with decompensated heart failure.

Circulation. Arrhythmia and electrophysiology·2011
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Nesiritide, a novel treatment for congestive heart failure (CHF), gained US approval in 2001. This recombinant B-type natriuretic peptide targets acute decompensated heart failure patients experiencing dyspnea.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biotechnology

Background:

  • Congestive heart failure (CHF) poses a significant clinical challenge.
  • Acute decompensated congestive heart failure (ADCHF) requires effective therapeutic interventions.
  • Nesiritide represents a novel therapeutic agent targeting CHF.

Purpose of the Study:

  • To evaluate the efficacy and safety of nesiritide for ADCHF.
  • To introduce a recombinant B-type natriuretic peptide for cardiovascular treatment.
  • To support the regulatory approval and market launch of nesiritide.

Main Methods:

  • Development of recombinant B-type natriuretic peptide (nesiritide).
  • Intravenous administration for patients with ADCHF.
  • Clinical trials assessing efficacy in patients with dyspnea.

Related Experiment Videos

Main Results:

  • US FDA approval and launch in August 2001.
  • Targeted treatment for ADCHF patients with dyspnea at rest or minimal activity.
  • Anticipated Marketing Authorization Application (MAA) filing in Europe by March 2002.

Conclusions:

  • Nesiritide offers a new treatment option for acute decompensated congestive heart failure.
  • Successful US market entry demonstrates therapeutic potential.
  • European regulatory submission planned, indicating global development strategy.